Whatsapp
Posted : Tuesday, August 20, 2024 07:45 PM
Company Profile:
Vaxcyte, Inc.
(Nasdaq: PCVX) is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases.
The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD).
The Company is re-engineering the way highly complex immunizations are made through modern synthetic techniques, including advanced chemistry and our exclusively licensed XpressCFTM cell-free protein synthesis platform.
Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits.
Vaxcyte’s pipeline also includes VAX-31, a 31-valent PCV candidate; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine program designed to prevent Shigella.
The Company is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.
For more information, visit www.
vaxcyte.
com.
Vaxcyte, headquartered in San Carlos, CA, went public in June 2020 and currently has a team of approximately 180 employees and anticipates continued, significant growth.
Following equity offerings in October 2022 and April 2023, which generated over $1.
1 billion in net proceeds, the Company’s balance sheet is further strengthened to advance its pipeline of novel vaccines, including VAX-24.
These financings followed positive data readouts from Vaxcyte’s Phase 1/2 proof-of-concept study evaluating VAX-24 in adults aged 18-64 and Phase 2 study in adults 65 and older.
The Company believes these results support a best-in-class potential for VAX-24, which was designed to replace the current standard-of-care in adults and children.
VAX-24 is being investigated for the prevention of IPD, which can be most serious for infants, young children, older adults and those with immune deficiencies or certain chronic health conditions.
Given the global impact of pneumococcal disease remains significant, the public health community continues to advocate for vaccines that can offer broader protection to prevent IPD.
Vaxcyte’s PCV franchise, consisting of VAX-24 and VAX-31, is designed specifically to address this need and has the potential to deliver the broadest protection for this very serious disease.
We believe that our PCVs could receive regulatory approval based on successful completion of clinical studies utilizing well-defined surrogate immune endpoints, consistent with how other PCVs have obtained regulatory approval in the past, rather than requiring clinical field efficacy studies.
Summary: This role on the Investor Relations (IR) & Corporate Communications team will provide coordination and execution of logistical and operational aspects of both the Investor Relations and Corporate Communications functions.
The Senior Coordinator will be an integral part of our mission and will entail communicating with external stakeholders such as research analysts and investors as well as collaborating with internal colleagues in areas such as Finance, Legal, Information Technology and our Executive Assistant (EA) team.
Essential Functions Investor Relations (IR) Meeting Logistics: A significant portion of role, on an ongoing basis, is to support all logistical aspects of our IR meetings including banking conferences, non-deal roadshows (NDRs) and ad hoc meetings.
Banking Conferences: Collaborate with Vaxcyte senior staff and executive assistants to determine preferred presentation date, register all company participants and reserve/coordinate hotel rooms for all conference attendees.
Support liaison between IR and conference coordinators to organize one-on-one meeting schedule and coordinate conference event participation for internal attendees.
Purchase conference webcast link and coordinate Vaxcyte website posting with IR website hosting vendor in conjunction with curtain raiser press release distribution.
Add final 1x1 meeting schedules to internal IR Outlook calendar and monitor conference portal for scheduling changes.
Coordinate meals, reservations and transportation for attendees as needed.
NDRs: Ensure dates are held on internal calendars for all attendees and work with EA team to flag any scheduling restrictions or conflicts.
Work with NDR sponsors to coordinate all logistics during NDRs including hotels, ground transportation and dining reservations.
Work with IR to create investor target lists for each event based on recent meeting history and IR strategy plan.
Responsible for annual JP Morgan conference in San Francisco: Secure meeting and sleeping rooms for all attendees.
Create separate meeting tracker to coordinate approximately 25 meetings over 3-4-day period.
Coordinate meals and transportation during the conference as needed.
All IR Meetings: Maintain internal IR Outlook calendar with all conferences, NDRs (including all 1x1 meetings during conferences and NDRs) and ad hoc meetings.
Ensure dates are held on internal calendars for all attendees and work with EA team to flag any scheduling restrictions or conflicts.
Work with IR agency to prepare background information for all meetings including investor profiles, meeting history and other relevant information to prepare management.
Maintain IR Customer Relationship Management (CRM) (IR Insight) by logging all IR meetings with internal and external attendees.
Ensure One Note meeting tracker is up to date with all relevant meeting information.
Responsible for all on-site IR meeting logistics including conference room bookings, greeting investors and food and beverages as needed.
Press Releases/Corporate Deck: Set up all press releases through wire services for distribution and submit Nasdaq disclosures.
Block internal calendars for all major announcements, including holding adequate time for follow-up calls post announcement and schedule any needed calls with research analysts and investors.
Support updates of corporate deck needed in conjunction with any announcements including proof reading.
Draft IR curtain raisers for conference participation and year-end earnings call and coordinate internal approvals.
Webcasts/Conference Calls: Set up logistics for all webcast events including year-end earnings call, data announcements and other external updates.
Work with Message Bank to coordinate all company preferences including operators, slides and speaker pre-recoding if necessary.
Provide on-site support during calls and coordinate with IT and Facilities for additional onsite help as needed.
Corporate Calendar/Website: Maintain corporate calendar with important dates: all IR conferences/NDRs, all corporate events and office closures, executive travel and external meeting dates, competitor earnings dates and special events.
Keep Investor Relations website up to date by adding and removing content as needed.
Corporate Communications: Responsible for daily media monitoring report distribution.
Support scheduling and logistics for all employee meetings, including the collection and/or development of new hire slides.
Participate in and support Culture Committee activities.
Support content gathering and related approvals (e.
g.
, legal waivers) for digital use on LinkedIn, intranet, etc.
; includes development of select content.
Learn basics about intranet, including how to post/manage content, to provide ad hoc support, as required.
Reports to: Vice President, Corporate Communications and Investor Relations Location: San Carlos, CA Compensation: The compensation package will be competitive and includes comprehensive benefits and an equity component.
Salary Range: $117,000 – $135,000 Send resumes to: careers@vaxcyte.
com Vaxcyte, Inc.
825 Industrial Road, Suite 300 San Carlos, CA 94070 We are an equal opportunity employer.
All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability or veteran status.
(Nasdaq: PCVX) is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases.
The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD).
The Company is re-engineering the way highly complex immunizations are made through modern synthetic techniques, including advanced chemistry and our exclusively licensed XpressCFTM cell-free protein synthesis platform.
Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits.
Vaxcyte’s pipeline also includes VAX-31, a 31-valent PCV candidate; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine program designed to prevent Shigella.
The Company is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.
For more information, visit www.
vaxcyte.
com.
Vaxcyte, headquartered in San Carlos, CA, went public in June 2020 and currently has a team of approximately 180 employees and anticipates continued, significant growth.
Following equity offerings in October 2022 and April 2023, which generated over $1.
1 billion in net proceeds, the Company’s balance sheet is further strengthened to advance its pipeline of novel vaccines, including VAX-24.
These financings followed positive data readouts from Vaxcyte’s Phase 1/2 proof-of-concept study evaluating VAX-24 in adults aged 18-64 and Phase 2 study in adults 65 and older.
The Company believes these results support a best-in-class potential for VAX-24, which was designed to replace the current standard-of-care in adults and children.
VAX-24 is being investigated for the prevention of IPD, which can be most serious for infants, young children, older adults and those with immune deficiencies or certain chronic health conditions.
Given the global impact of pneumococcal disease remains significant, the public health community continues to advocate for vaccines that can offer broader protection to prevent IPD.
Vaxcyte’s PCV franchise, consisting of VAX-24 and VAX-31, is designed specifically to address this need and has the potential to deliver the broadest protection for this very serious disease.
We believe that our PCVs could receive regulatory approval based on successful completion of clinical studies utilizing well-defined surrogate immune endpoints, consistent with how other PCVs have obtained regulatory approval in the past, rather than requiring clinical field efficacy studies.
Summary: This role on the Investor Relations (IR) & Corporate Communications team will provide coordination and execution of logistical and operational aspects of both the Investor Relations and Corporate Communications functions.
The Senior Coordinator will be an integral part of our mission and will entail communicating with external stakeholders such as research analysts and investors as well as collaborating with internal colleagues in areas such as Finance, Legal, Information Technology and our Executive Assistant (EA) team.
Essential Functions Investor Relations (IR) Meeting Logistics: A significant portion of role, on an ongoing basis, is to support all logistical aspects of our IR meetings including banking conferences, non-deal roadshows (NDRs) and ad hoc meetings.
Banking Conferences: Collaborate with Vaxcyte senior staff and executive assistants to determine preferred presentation date, register all company participants and reserve/coordinate hotel rooms for all conference attendees.
Support liaison between IR and conference coordinators to organize one-on-one meeting schedule and coordinate conference event participation for internal attendees.
Purchase conference webcast link and coordinate Vaxcyte website posting with IR website hosting vendor in conjunction with curtain raiser press release distribution.
Add final 1x1 meeting schedules to internal IR Outlook calendar and monitor conference portal for scheduling changes.
Coordinate meals, reservations and transportation for attendees as needed.
NDRs: Ensure dates are held on internal calendars for all attendees and work with EA team to flag any scheduling restrictions or conflicts.
Work with NDR sponsors to coordinate all logistics during NDRs including hotels, ground transportation and dining reservations.
Work with IR to create investor target lists for each event based on recent meeting history and IR strategy plan.
Responsible for annual JP Morgan conference in San Francisco: Secure meeting and sleeping rooms for all attendees.
Create separate meeting tracker to coordinate approximately 25 meetings over 3-4-day period.
Coordinate meals and transportation during the conference as needed.
All IR Meetings: Maintain internal IR Outlook calendar with all conferences, NDRs (including all 1x1 meetings during conferences and NDRs) and ad hoc meetings.
Ensure dates are held on internal calendars for all attendees and work with EA team to flag any scheduling restrictions or conflicts.
Work with IR agency to prepare background information for all meetings including investor profiles, meeting history and other relevant information to prepare management.
Maintain IR Customer Relationship Management (CRM) (IR Insight) by logging all IR meetings with internal and external attendees.
Ensure One Note meeting tracker is up to date with all relevant meeting information.
Responsible for all on-site IR meeting logistics including conference room bookings, greeting investors and food and beverages as needed.
Press Releases/Corporate Deck: Set up all press releases through wire services for distribution and submit Nasdaq disclosures.
Block internal calendars for all major announcements, including holding adequate time for follow-up calls post announcement and schedule any needed calls with research analysts and investors.
Support updates of corporate deck needed in conjunction with any announcements including proof reading.
Draft IR curtain raisers for conference participation and year-end earnings call and coordinate internal approvals.
Webcasts/Conference Calls: Set up logistics for all webcast events including year-end earnings call, data announcements and other external updates.
Work with Message Bank to coordinate all company preferences including operators, slides and speaker pre-recoding if necessary.
Provide on-site support during calls and coordinate with IT and Facilities for additional onsite help as needed.
Corporate Calendar/Website: Maintain corporate calendar with important dates: all IR conferences/NDRs, all corporate events and office closures, executive travel and external meeting dates, competitor earnings dates and special events.
Keep Investor Relations website up to date by adding and removing content as needed.
Corporate Communications: Responsible for daily media monitoring report distribution.
Support scheduling and logistics for all employee meetings, including the collection and/or development of new hire slides.
Participate in and support Culture Committee activities.
Support content gathering and related approvals (e.
g.
, legal waivers) for digital use on LinkedIn, intranet, etc.
; includes development of select content.
Learn basics about intranet, including how to post/manage content, to provide ad hoc support, as required.
Reports to: Vice President, Corporate Communications and Investor Relations Location: San Carlos, CA Compensation: The compensation package will be competitive and includes comprehensive benefits and an equity component.
Salary Range: $117,000 – $135,000 Send resumes to: careers@vaxcyte.
com Vaxcyte, Inc.
825 Industrial Road, Suite 300 San Carlos, CA 94070 We are an equal opportunity employer.
All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability or veteran status.
• Phone : NA
• Location : 825 Industrial Rd Ste 300, San Carlos, CA
• Post ID: 9004982372
